(Q46714567)

24 December 2017

title

Duration of adjuvant trastuzumab: shorter beats longer (English)

1 reference

24 December 2017

1 reference

1

1 reference

24 December 2017

language of work or name

English

0 references

publication date

18 July 2013

1 reference

24 December 2017

published in

The Lancet

1 reference

24 December 2017

volume

382

1 reference

24 December 2017

issue

9897

1 reference

24 December 2017

page(s)

1010-1011

1 reference

24 December 2017

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961448-8

7 January 2021

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961448-8

7 January 2021

Adjuvant trastuzumab in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961448-8

7 January 2021

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961448-8

7 January 2021

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961448-8

7 January 2021

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961448-8

7 January 2021

Metastatic behavior of breast cancer subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961448-8

7 January 2021

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961448-8

7 January 2021

Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961448-8

7 January 2021

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961448-8

7 January 2021

Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961448-8

7 January 2021

Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961448-8

7 January 2021

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961448-8

7 January 2021

10.1016/S0140-6736(13)61448-8

Identifiers

DOI

1 reference

24 December 2017

release_3uxyi3t2m5fhhkyggjqgel7yw4

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3uxyi3t2m5fhhkyggjqgel7yw4

24 November 2022

mapped directly with Wikidata item

1 reference

24 December 2017